{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:11:42Z","timestamp":1783905102157,"version":"3.55.0"},"reference-count":57,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    The frequency of ABO, Rh and Kell blood group antigens differs among populations of different ethnic ancestry. There are low-frequency antigens (&lt;1%) and high-frequency antigens (&gt;90%). A rare blood group is defined as the absence of a high-frequency antigen in the general population, as well as absence of multiple frequent antigens within a single or multiple blood group systems.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Aim<\/jats:bold>\n                    : To perform red blood cell typing and to calculate the antigen and phenotype frequencies, in order to identify rare blood group donors within the clinically most important \u0410\u0412\u041e, Rh and Kell systems.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Material and Methods<\/jats:bold>\n                    : \u0410\u0412\u041e, Rh (D, C, E, c, e) and Kell (K) antigen typing was performed using specific monoclonal sera and microplate technique, while Cellano (k) typing was performed with a monoclonal anti-k, antihuman globulin and column agglutination technique. Weak ABO subgroups were determined using the absorption elution method or molecular genotyping (PCR-SSP).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : ABO antigen frequency is: A (40.89%), O (34.22%), B (16.97%), AB (7.92%) and weak ABO subgroups (0, 009 %). The established genotypes were AxO1 (0, 0026%) and AxB (0, 001%). Rh antigen frequency is: D (85.79%), C (71.7%), c (76.0%), E (26.0%) and \u0435 (97.95%). The most common Rh pheno-type is the DCcee (32.7%) while the rarest phenotype is the DCCEE phenotype (0. 003%). The prevalence of K and k antigen is 7.5% and 99.94%, respectively. The frequency of the rare phenotype K+k- is 0.06%.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    : Large scale phenotyping of blood group antigens enables the identification of blood donors with rare blood groups for patients with rare phenotypes or with antibodies to high-frequency antigens and to frequent antigens within one or more blood group systems.\n                  <\/jats:p>","DOI":"10.2478\/prilozi-2022-0021","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T14:06:38Z","timestamp":1657721198000},"page":"77-87","source":"Crossref","is-referenced-by-count":7,"title":["Rare Blood Groups in ABO, Rh, Kell Systems \u2013 Biological and Clinical Significance"],"prefix":"10.2478","volume":"43","author":[{"given":"Elena","family":"Ristovska","sequence":"first","affiliation":[{"name":"Institute for transfusion medicine , St Cyril and Methodius University , Medical Faculty , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0422atjana Makarovska","family":"Bojadjieva","sequence":"additional","affiliation":[{"name":"Institute for transfusion medicine , St Cyril and Methodius University , Medical Faculty , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0415milija","family":"Velkova","sequence":"additional","affiliation":[{"name":"Institute for transfusion medicine , St Cyril and Methodius University , Medical Faculty , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0410nita Hristova","family":"Dimceva","sequence":"additional","affiliation":[{"name":"Institute for transfusion medicine , St Cyril and Methodius University , Medical Faculty , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Todorovski","sequence":"additional","affiliation":[{"name":"Institute for transfusion medicine , St Cyril and Methodius University , Medical Faculty , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Tashkovska","sequence":"additional","affiliation":[{"name":"Institute for transfusion medicine , St Cyril and Methodius University , Medical Faculty , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rada Grubovic","family":"Rastvorceva","sequence":"additional","affiliation":[{"name":"Institute for transfusion medicine , St Cyril and Methodius University , Medical Faculty , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijan","family":"Bosevski","sequence":"additional","affiliation":[{"name":"Clinic of cardiology , St Cyril and Methodius University , Medical Faculty , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"2026071214263427721_j_prilozi-2022-0021_ref_001","doi-asserted-by":"crossref","unstructured":"1. Anstee DJ. The relationship between blood groups and disease. Blood 2010;115:4635\u201343.10.1182\/blood-2010-01-26185920308598","DOI":"10.1182\/blood-2010-01-261859"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_002","doi-asserted-by":"crossref","unstructured":"2. Groot HE, Villegas Sierra LE, Said MA, et al. Genetically determined ABO blood group and its associations with health and disease. Arteriosclerosis Thrombosis and Vascular Biology 2020;40:830\u2013838.10.1161\/ATVBAHA.119.31365831969017","DOI":"10.1161\/ATVBAHA.119.313658"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_003","doi-asserted-by":"crossref","unstructured":"3. Jenkins PV, O\u2019Donnel JS. ABO blood group determinates plasma levels of von Willebrand factor. Transfusion 2006; 46 (10): 1836-1844.10.1111\/j.1537-2995.2006.00975.x17002642","DOI":"10.1111\/j.1537-2995.2006.00975.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_004","doi-asserted-by":"crossref","unstructured":"4. Zhang H, Mooney CJ, Reilly MP. ABO Blood Groups and Cardiovascular Diseases. Int J Vasc Med 2012; 2012:641917.10.1155\/2012\/641917348550123133757","DOI":"10.1155\/2012\/641917"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_005","doi-asserted-by":"crossref","unstructured":"5. Wu O, Bayoumi N, Vickers MA, Clark P. ABO (H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Hae-most 2008; 6:62\u20139.10.1111\/j.1538-7836.2007.02818.x17973651","DOI":"10.1111\/j.1538-7836.2007.02818.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_006","doi-asserted-by":"crossref","unstructured":"6. Hiltunen LM, Laivuori H, Rautanen A, et al. Blood group AB and factor V Leiden as risk factors for pre-eclampsia: A population-based nested case-control study. Thromb Res 2009;124:167\u201373.10.1016\/j.thromres.2008.11.01219110300","DOI":"10.1016\/j.thromres.2008.11.012"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_007","doi-asserted-by":"crossref","unstructured":"7. Iodice S, Maisonneuve P, Botteri E, et al. ABO blood group and cancer. Eur J Cancer 2010; 46: 3345\u20133350.10.1016\/j.ejca.2010.08.00920833034","DOI":"10.1016\/j.ejca.2010.08.009"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_008","doi-asserted-by":"crossref","unstructured":"8. Wang Z, Liu L, Ji J et al. ABO blood group system and gastric cancer: a case-control study and meta-analysis. Int J Mol Sci 2012; 13: 13308\u201313321.10.3390\/ijms131013308349732823202954","DOI":"10.3390\/ijms131013308"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_009","doi-asserted-by":"crossref","unstructured":"9. Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009; 101: 424\u2013431.10.1093\/jnci\/djp020265709519276450","DOI":"10.1093\/jnci\/djp020"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_010","doi-asserted-by":"crossref","unstructured":"10. Gates MA, Wolpin BM, Cramer DW, et al. ABO blood group and incidence of epithelial ovarian cancer. Int J Cancer 2011;128:482\u20136.10.1002\/ijc.25339294696220309936","DOI":"10.1002\/ijc.25339"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_011","doi-asserted-by":"crossref","unstructured":"11. Matsushita S, Imamura T, Mizuta T, Hanada M. Acquired B antigen and polyagglutination in a patient with gastric cancer. Jpn J Surg 1983; 13 (6): 540\u20132.10.1007\/BF024695006672386","DOI":"10.1007\/BF02469500"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_012","unstructured":"12. Voskova D, Valekova L, Fedorova J, et al. Leukemic cells and aberrant phenotypes in acute leukemia patients: a flow cytometry analysis. Neo-plasma 2003; 50: 422-7."},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_013","doi-asserted-by":"crossref","unstructured":"13. Bianco-Miotto T, Hussey DJ, Day TK, O\u2019Keefe DS, Dobrovic A. DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PloS one 2009;4 (3):e4788.10.1371\/journal.pone.0004788265078019274076","DOI":"10.1371\/journal.pone.0004788"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_014","doi-asserted-by":"crossref","unstructured":"14. Faruque AS., Mahalanabis D, Hoque SS, Albert MJ. The relationship between ABO blood groups and susceptibility to diarrhea due to Vibrio cholerae 0139. Clinical Infectious Diseases 1994;18 (5):827\u20138.10.1093\/clinids\/18.5.8278075282","DOI":"10.1093\/clinids\/18.5.827"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_015","doi-asserted-by":"crossref","unstructured":"15. Rowe JA, Handel IG, Thera MA, et al. Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proceedings of the National Academy of Sciences of the United States of America 2007;104(44):17471\u20136.10.1073\/pnas.0705390104207728017959777","DOI":"10.1073\/pnas.0705390104"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_016","doi-asserted-by":"crossref","unstructured":"16. Zhang Y, Garner R, Salehi S, et al. Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies. Ann Hematol 2021;100 (5):1123-1132.10.1007\/s00277-021-04489-w793954333686492","DOI":"10.1007\/s00277-021-04489-w"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_017","doi-asserted-by":"crossref","unstructured":"17. Hosoi E. Biological and clinical aspects of ABO blood group system. The Journal of Medical Investigation 2008; 55 (3-4):174-82.10.2152\/jmi.55.17418797129","DOI":"10.2152\/jmi.55.174"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_018","doi-asserted-by":"crossref","unstructured":"18. Wagner FF, Moulds JM, Flegel WA. Genetic mechanisms of Rhesus box variation. Blood 2005;45(3):338\u201344.","DOI":"10.1111\/j.1537-2995.2005.04339.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_019","doi-asserted-by":"crossref","unstructured":"19. Allen FH, Krabbe SM, Corcoran PA. A new phenotype (McLeod) in the Kell blood-group system. Vox Sanguinis 1961; 6 (5): 555\u201360.10.1111\/j.1423-0410.1961.tb03203.x13860532","DOI":"10.1111\/j.1423-0410.1961.tb03203.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_020","doi-asserted-by":"crossref","unstructured":"20. Daniels G, Poole J, de Silva M, et al. The clinical significance of blood group antibodies. Transfusion Med 2002; 12: 287-295.10.1046\/j.1365-3148.2002.00399.x12383334","DOI":"10.1046\/j.1365-3148.2002.00399.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_021","doi-asserted-by":"crossref","unstructured":"21. Klein H, Anstee DJ. Mollison\u2019s Blood Trans-fusion in Clinical Medicine, 11th edn. Oxford: Blackwell Science, 2005.10.1002\/9780470986868","DOI":"10.1002\/9780470986868"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_022","doi-asserted-by":"crossref","unstructured":"22. Daniels G. and members of the ISBT Working Party on Terminology for Red Cell Surface Antigens. Blood group terminology 2004. Vox Sang 2004; 87: 304-316.10.1111\/j.1423-0410.2004.00564.x15585029","DOI":"10.1111\/j.1423-0410.2004.00564.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_023","unstructured":"23. Dean L. Blood Groups and Red Cell Antigens. Bethesda (MD): National Center for Biotechnology Information (US); 2005. Chapter 8, The Kell blood group. Available from:https:\/\/www.ncbi.nlm.gov\/books\/NBK2270."},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_024","unstructured":"24. Reesnik HW. Donors with a rare phenol (geno) type. Vox Sang 2008; 95: 236-53.10.1111\/j.1423-0410.2008.01084.x19121189"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_025","unstructured":"25. Peyrard T. The rare blood groups: a public health challenge. Transfus Clin Biol 2008; 15: 109-19.10.1016\/j.tracli.2008.02.00118403227"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_026","doi-asserted-by":"crossref","unstructured":"26. Thornton NM, Grimsley SP. Clinical significance of antibodies to antigens in the ABO, MNS, P1PK, Rh, Lutheran, Kell, Lewis, Duffy, Kidd, Diego, Yt, and Xg blood group systems. Immunohematology 2019; 35 (3):95-101.10.21307\/immunohematology-2020-021","DOI":"10.21307\/immunohematology-2020-021"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_027","unstructured":"27. Rh null the Rarest Blood Type on Earth, Has Been Called the \u201cGolden Blood\u201d. Curiosity.com. Archived from the original on 5 December 2019. Retrieved 2019-06-05."},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_028","unstructured":"28. Bailey P. \u201cThe man with the golden blood\u201d. Mosaic Science. Mosaic. Retrieved 16 January 2019."},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_029","unstructured":"29. Quershi A, Salman M, Moiz B. Rh null: a rare blood group phenotype.J Pak Med Assoc. 2010;60 (11):960-961."},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_030","doi-asserted-by":"crossref","unstructured":"30. Gabra GS, Bruce M, Watt A, Mitchell R. Anti-Rh 29 in a primigravida with rhesus null syndrome resulting in haemolytic disease of the newborn. Vox Sang. 1987;53(3):143-6.10.1111\/j.1423-0410.1987.tb04938.x3120413","DOI":"10.1111\/j.1423-0410.1987.tb04938.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_031","doi-asserted-by":"crossref","unstructured":"31. Yu LC, Twu YC, Chang CY, Lin M. \u201cMolecular basis of the Kell-null phenotype: a mutation at the splice site of human KEL gene abolishes the expression of blood group antigens\u201d. The Journal of Biological Chemistry. 2001; 276 (13): 10247\u201352.10.1074\/jbc.M00987920011134029","DOI":"10.1074\/jbc.M009879200"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_032","doi-asserted-by":"crossref","unstructured":"32. Lin M, Wang CL, Chen FS, Ho LH. Fatal haemolytic transfusion reaction due to anti-Ku in a Knull patient. Immunohematol. 2003;19:19\u201321.10.21307\/immunohematology-2019-469","DOI":"10.21307\/immunohematology-2019-469"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_033","doi-asserted-by":"crossref","unstructured":"33. Russo DC, Lee S, Reid ME, Redman CM. Point mutations causing the McLeod phenotype. Trans-fusion. 2002; 42 (3): 287\u201393.10.1046\/j.1537-2995.2002.00049.x11961232","DOI":"10.1046\/j.1537-2995.2002.00049.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_034","doi-asserted-by":"crossref","unstructured":"34. Mallick S, Kotasthane DS, Chowdhury PS, Sarkar S: Bombay blood group: is prevalence decreasing with urbanization and the decreasing rate of consanguineous marriage. Asian J Transfus Sci 2015;9:129-132.10.4103\/0973-6247.162695456213026420929","DOI":"10.4103\/0973-6247.162695"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_035","doi-asserted-by":"crossref","unstructured":"35. Oriol R, Candelier JJ, Mollicone R: Molecular genetics of H. Vox Sang 2000;78(2):105-108.","DOI":"10.1111\/j.1423-0410.2000.tb00046.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_036","doi-asserted-by":"crossref","unstructured":"36. Mourat AE. The establishment of an international panel of blood donors of rare types. Vox Sang 1965; 10: 129-132.10.1111\/j.1423-0410.1965.tb04330.x14339220","DOI":"10.1159\/000464980"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_037","doi-asserted-by":"crossref","unstructured":"37. Anstee D. Rare blood. An ISBT working party report on rare blood donors. Vox Sang 1999; 77:58-62.10.1046\/j.1423-0410.1999.7710058.x","DOI":"10.1046\/j.1423-0410.1999.7710058.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_038","doi-asserted-by":"crossref","unstructured":"38. Nance S, Schanrberg EA, Thronton N, et al. International rare donor panels: a review. Vox sang 2015.10.1111\/vox.12357","DOI":"10.1111\/vox.12357"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_039","unstructured":"39. Makarovska-Bojadzieva T, Blagoevska M, Kolevski P, Kostovska S. Optimal blood gouping and antibody screenining for safe transfusion. Contributions, Sec.Biol.Med. Sci. MASA 2009; 30 (1): 119-128."},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_040","unstructured":"40. Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine, 10th ed. 1997; Blackwell Scientific Publications, Oxford."},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_041","doi-asserted-by":"crossref","unstructured":"41. Daniels G, Bromilow I. Essential Guide to Blood Groups, 2nd Edition. 2011, Wiley Blackwel.10.1002\/9781444325188","DOI":"10.1002\/9781444325188"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_042","unstructured":"42. Issit PD, Applied blood group serology, 3rd ed. 1985; p.222; Montgomery Scientific Publications, Miami, Florida, U.S.A."},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_043","doi-asserted-by":"crossref","unstructured":"43. Mitra R, Mishra N, Rath GP. Blood group systems. Indian J Anaesth. 2014;58(5):524-528.10.4103\/0019-5049.144645","DOI":"10.4103\/0019-5049.144645"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_044","doi-asserted-by":"crossref","unstructured":"44. Kahar MA, Patel RD. Phenotype frequencies of blood group systems (Rh, Kell, Kidd, Duffy, MNS, P, Lewis, and Lutheran) in blood donors of south Gujarat, India. Asian J Transfus Sci. 2014; 8(1): 51\u201355.10.4103\/0973-6247.126693","DOI":"10.4103\/0973-6247.126693"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_045","doi-asserted-by":"crossref","unstructured":"45. Reid ME, Lomas-Francis C. The Blood Group Antigen Facts Book. Second ed. 2004, New York: Elsevier Academic Press.10.1016\/B978-012586585-2\/50029-9","DOI":"10.1016\/B978-012586585-2\/50029-9"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_046","unstructured":"46. Makroo RN, Bahtia A, Gupta R, Philip J. Prevalence of Rh, Duffy, Kell, Kidd &  MNSs blood group antigens in the Indian blood donor population. Indian J Med Res. 2013 Mar; 137(3): 521\u2013526."},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_047","doi-asserted-by":"crossref","unstructured":"47. Makarovska Bojadzieva T, Velkova E, Blagoevska M. The impact of extended typing on red cell alloimmunization in transfused patients. Open Access Maced J med Sci. 2017; 5(2):107-111.10.3889\/oamjms.2017.054","DOI":"10.3889\/oamjms.2017.054"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_048","unstructured":"48. Stefanovska V.Alloimunization to blood group antigens. Doctoral Thesis. St Cyril and Methodius University, Medical Faculty, Skopje, 1992."},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_049","doi-asserted-by":"crossref","unstructured":"49. Goldstein J, Siviglia G, Hurst R, Lenny L, Reich L. Group B erythrocytes enzymatically converted to group O survive normally in A, B, and O individuals. Science. 1982;215:168\u201370.10.1126\/science.6274021","DOI":"10.1126\/science.6274021"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_050","doi-asserted-by":"crossref","unstructured":"50. Goldstein J. Conversion of ABO blood groups. Transfus Med Rev. 1989;3:206\u201312.10.1016\/S0887-7963(89)70080-8","DOI":"10.1016\/S0887-7963(89)70080-8"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_051","doi-asserted-by":"crossref","unstructured":"51. Liu QP, Sulzenbacher G, Yuan H, Bennett EP, Pietz G, Saunders K, et al. Bacterial glycosidases for the production of universal red blood cells. Nat Biotechnol. 2007;25:454\u201364.10.1038\/nbt129817401360","DOI":"10.1038\/nbt1298"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_052","doi-asserted-by":"crossref","unstructured":"52. Kobayashi T, Liu D, Ogawa H, Miwa Y, Nagasaka T, Maruyama S, et al. Alternative strategy for overcoming ABO incompatibility. Transplantation. 2007;83:1284\u20136.10.1097\/01.tp.0000260634.85690.c417496551","DOI":"10.1097\/01.tp.0000260634.85690.c4"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_053","doi-asserted-by":"crossref","unstructured":"53. Nacharaju P, Boctor FN, Manjula BN, Acharya SA. Surface decoration of red blood cells with maleimidophenyl-polyethylene glycol facilitated by thiolation with iminothiolane: an approach to mask A, B, and D antigens to generate universal red blood cells. Transfusion. 2005 Mar;45(3):374-83.10.1111\/j.1537-2995.2005.04290.x15752155","DOI":"10.1111\/j.1537-2995.2005.04290.x"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_054","doi-asserted-by":"crossref","unstructured":"54. Hashemi-Najafabadi S, Vasheghani-Farahani E, Shojaosadati SA, Rasaee MJ, Armstrong JK, Moin M, et al. A method to optimize PEG-coating of red blood cells. Bioconjug Chem. 2006;17:1288\u201393.10.1021\/bc060057w16984140","DOI":"10.1021\/bc060057w"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_055","doi-asserted-by":"crossref","unstructured":"55. Yoojin S, Kyung-Hwa S, Hyung HK, Hyung-Sik K. Current Advances in Red Blood Cell Generation Using Stem Cells from Diverse Sources. Stem Cells International, vol. 2019. https:\/\/doi.org\/10.1155\/2019\/9281329.670131631467565","DOI":"10.1155\/2019\/9281329"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_056","doi-asserted-by":"crossref","unstructured":"56. Tarafdar S, Mondy P, Powley T, et al. Understanding the demand for phenotyped red blood cell units and requests to perform molecular red blood cell typing for Australian patients. Transfusion and Apheresis Science 2020; 60(1):102968.","DOI":"10.1016\/j.transci.2020.102968"},{"key":"2026071214263427721_j_prilozi-2022-0021_ref_057","unstructured":"57. Liu Z, Zeng R, Chen Q, et al. Genotyping for Kidd, Kell, Duffy, Scianna, and RHCE blood group antigens polymorphisms in Jiangsu Chinese Han Chin Med J 2012;125(6):1076-81.."}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2022-0021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:41:00Z","timestamp":1783903260000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2022-0021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,13]]},"published-print":{"date-parts":[[2022,7,1]]}},"alternative-id":["10.2478\/prilozi-2022-0021"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2022-0021","relation":{},"ISSN":["1857-8985"],"issn-type":[{"value":"1857-8985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}